Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zilli

Showing results (1-10 of 234) with videos related to

Pageof 24
Sort By:
European Urology Oncology|February 28, 2024
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007Thomas Zilli, Piet Ost
Prostate Cancer and Prostatic Diseases|April 29, 2022
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscapeVérane Achard, Thomas Zilli
Prostate Cancer and Prostatic Diseases|February 6, 2025
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancerNicolas Vial, Thomas Zilli
The Journal of Urology|May 11, 2015
Re: Prophylactic Sildenafil Citrate Improves Select Aspects of Sexual Function in Men Treated with Radiotherapy for Prostate Cancer: M. J. Zelefsky, D. Shasha, R. D. Branco, M. Kollmeier, R. E. Baser, X. Pei, R. Ennis, R. Stock, N. Bar-Chama and J. P. Mulhall J Urol 2014; 192: 868-874Thomas Zilli, Raymond Miralbell
Prostate Cancer and Prostatic Diseases|August 13, 2024
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy settingVérane Achard, Thomas Zilli
International Journal of Radiation Oncology, Biology, Physics|September 1, 2024
Toxicity After Prostate Radiation Therapy: Addressing the Transurethral Resection of the Prostate (TURP) ChallengeRagu Ratnakumaran, Thomas Zilli
Prostate Cancer and Prostatic Diseases|November 25, 2025
Chasing the Culprit: targeting metastatic index lesions in oligometastatic hormone-sensitive prostate cancerSalvatore Cozzi, Thomas Zilli
Oncotarget|October 23, 2018
Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?Thomas Zilli, Piet Ost
International Journal of Radiation Oncology, Biology, Physics|February 15, 2015
High-dose salvage radiation therapy for prostate cancer after relapse: in regard to D'Angelillo et alThomas Zilli, Raymond Miralbell
International Journal of Radiation Oncology, Biology, Physics|February 25, 2020
In Regard to Qi et alVérane Achard, Thomas Zilli
Pageof 24

Showing results (1-10 of 234) with videos related to

Sort By:
Pageof 24
European Urology Oncology|February 28, 2024
Reply to Francesco Montorsi, Giorgio Gandaglia, Francesco Barletta, and Alberto Briganti's Letter to the Editor re: Piet Ost, Shankar Siva, Sugmund Brabrand, et al. PEACE V-Salvage Treatment of Oligorecurrent Nodal Prostate Cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.09.007Thomas Zilli, Piet Ost
Prostate Cancer and Prostatic Diseases|April 29, 2022
Prostate cancer intensity-modulated radiotherapy and long term genitourinary toxicity: an evolving therapeutic landscapeVérane Achard, Thomas Zilli
Prostate Cancer and Prostatic Diseases|February 6, 2025
Stereotactic body radiotherapy: a second chance for radio-recurrent prostate cancerNicolas Vial, Thomas Zilli
The Journal of Urology|May 11, 2015
Re: Prophylactic Sildenafil Citrate Improves Select Aspects of Sexual Function in Men Treated with Radiotherapy for Prostate Cancer: M. J. Zelefsky, D. Shasha, R. D. Branco, M. Kollmeier, R. E. Baser, X. Pei, R. Ennis, R. Stock, N. Bar-Chama and J. P. Mulhall J Urol 2014; 192: 868-874Thomas Zilli, Raymond Miralbell
Prostate Cancer and Prostatic Diseases|August 13, 2024
Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy settingVérane Achard, Thomas Zilli
International Journal of Radiation Oncology, Biology, Physics|September 1, 2024
Toxicity After Prostate Radiation Therapy: Addressing the Transurethral Resection of the Prostate (TURP) ChallengeRagu Ratnakumaran, Thomas Zilli
Prostate Cancer and Prostatic Diseases|November 25, 2025
Chasing the Culprit: targeting metastatic index lesions in oligometastatic hormone-sensitive prostate cancerSalvatore Cozzi, Thomas Zilli
Oncotarget|October 23, 2018
Metastasis-directed therapy: a new standard for oligorecurrent prostate cancer?Thomas Zilli, Piet Ost
International Journal of Radiation Oncology, Biology, Physics|February 15, 2015
High-dose salvage radiation therapy for prostate cancer after relapse: in regard to D'Angelillo et alThomas Zilli, Raymond Miralbell
International Journal of Radiation Oncology, Biology, Physics|February 25, 2020
In Regard to Qi et alVérane Achard, Thomas Zilli
Pageof 24